Real-World Experience of the Comparative Effectiveness and Safety of Combination Therapy with Remdesivir and Monoclonal Antibodies versus Remdesivir Alone for Patients with Mild-to-Moderate COVID-19 and Immunosuppression: A Retrospective Single-Center Study in Aichi, Japan

The coronavirus disease (COVID-19) pandemic continues to threaten global public health. Remdesivir and monoclonal antibodies have shown promise for COVID-19 treatment of patients who are immunocompromised, including those with cancer, transplant recipients, and those with autoimmune disorder. Howeve...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:Viruses
المؤلفون الرئيسيون: Jun Hirai, Nobuaki Mori, Daisuke Sakanashi, Wataru Ohashi, Yuichi Shibata, Nobuhiro Asai, Hideo Kato, Mao Hagihara, Hiroshige Mikamo
التنسيق: مقال
اللغة:الإنجليزية
منشور في: MDPI AG 2023-09-01
الموضوعات:
COVID-19
immunocompromised
remdesivir
monoclonal antibodies
combination
الوصول للمادة أونلاين:https://www.mdpi.com/1999-4915/15/9/1952

الانترنت

https://www.mdpi.com/1999-4915/15/9/1952

مواد مشابهة